Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC

March 15th 2021

Dr. Spira discusses the historical challenges of targeting KRAS, key findings from the phase 2 CodeBreaK 100 trial with sotorasib in KRAS G12C-mutant solid tumors, and the next steps of development for KRAS inhibitors in oncology.

Selpercatinib and Pralsetinib Generate Enthusiasm in RET Fusion+ NSCLC

March 15th 2021

Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.

Osimertinib Continues to Enhance Outcomes in EGFR+ NSCLC

March 12th 2021

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

FDA Grants Fast Track Status to Poziotinib for HER2 Exon 20–Mutated NSCLC

March 11th 2021

The FDA has granted a fast track designation to poziotinib for use in previously treated patients with HER2 exon 20 mutations.

Levy Lauds Biomarker-Driven Data in Lung Cancer

March 11th 2021

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Agents Targeting MET, RET, and Previously “Undruggable” KRAS Advance Treatment in NSCLC

March 11th 2021

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

ctDNA and Molecular Alterations Among Important Treatment Considerations in CRC

March 11th 2021

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

FDA Approves Companion Diagnostic for Lorlatinib in ALK+ NSCLC

March 9th 2021

The FDA has approved the VENTANA ALK CDx assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.

Frontline Ibrutinib Shows Sustained Survival Benefit in TP53-Aberrant CLL

March 8th 2021

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC

March 4th 2021

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 4th 2021

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

FDA Expands Approval of Lorlatinib for Frontline ALK+ NSCLC

March 4th 2021

The FDA has expanded the indication for lorlatinib to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

The Many Shades of KRAS: Investigators Seek to Exploit Heterogeneity in Mutations

March 3rd 2021

KRAS has topped the most wanted list of therapeutic targets in oncology for decades, but it has resolutely resisted all efforts, garnering it a reputation as undruggable.

FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC

March 1st 2021

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.

FDA Approval Sought for Ivosidenib in Previously Treated IDH1-Mutant Cholangiocarcinoma

March 1st 2021

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Biomarker-Guided Therapies, Novel Combos Take Center Stage in Urothelial Carcinoma

February 23rd 2021

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 19th 2021

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled

February 18th 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Next-Generation Sequencing Reveals Potentially Actionable Mutations in Sarcoma

February 18th 2021

February 18, 2021 — The use of next-generation sequencing demonstrated that 34% of patients with sarcoma had potentially actionable mutations.